Supplementary material

Cytotoxity-guided isolation of two new phenolic derivatives from *Dryopteris fragrans* (L.) Schott

Tong Zhang 1, Li Wang 2, De-Hua Duan 1, Yi-Hao Zhang 1, Sheng-Xiong Huang 2,* and Ying Chang 1,*

¹ College of Life Science, Northeast Agricultural University, Harbin 150030, China; <u>shmzhyzt@163.com</u> (T.Z.); myrddh@163.com(D.-H.D.); yhzneau@163.com(Y.-H.Z.)

- ² State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute
- of Botany, Chinese Academy of Sciences, Kunming 650201, China; jasminewangli@126.com (L.W.)
- * Correspondence: <u>sxhuang@mail.kib.ac.cn</u> (S.-X.H.); <u>changying@neau.edu.cn</u> (C.Y.); Tel.: +86-871-6521-5112 (S.-X.H.); +86-451-5519-0410 (C.Y.)

Contents of Supporting Information

No.	Contents	Page
1	Figure S1. The first round screening of cytotoxic sites of crude extract from <i>Dryopteris</i> fragrans.	3
2.	Figure S2. The second round screening of cytotoxic sites of fractions from <i>Dryopteris</i> fragrans.	3-4
3.	Figure S3. ¹ H NMR spectrum of compound 1 recorded in CDCl ₃ at 600 MHz.	5
4.	Figure S4. ¹³ C NMR spectrum of compound 1 recorded in CDCl ₃ at 150 MHz.	5
5.	Figure S5. HSQC spectrum of compound 1 recorded in CDCl3 at 600 MHz.	6
6.	Figure S6. HMBC spectrum of compound 1 recorded in CDCl3 at 600 MHz.	6
7	Figure S7. UV spectrum of compound 1.	7
8	Figure S8. HR-ESI-MS spectrum of compound 1.	8
9	Figure S9. CD spectrum of compound 1.	9
10	Figure S10. IR spectrum of compound 1 .	9
11	Figure S11. ¹ H NMR spectrum of the mixture (2 and 3) recorded in CDCl ₃ at 400 MHz.	10
12	Figure S12. ¹³ C NMR spectrum of the mixture (2 and 3) recorded in CDCl ₃ at 100 MHz.	10
13	Figure S13. ESI-MS spectrum of the mixture (2 and 3).	11
14	Figure S14. ¹ H NMR spectrum of compound 2a recorded in CDCl ₃ at 400 MHz.	11
15	Figure S15. ¹³ C NMR spectrum of compound 2a recorded in CDCl ₃ at 100 MHz.	12
16	Figure S16. ¹ H NMR spectrum of compound 2 recorded in CDCl ₃ at 600 MHz.	12
17	Figure S17. ¹³ C NMR spectrum of compound 2 recorded in CDCl ₃ at 150 MHz.	13
18	Figure S18. HSQC spectrum of compound 2 recorded in CDCl ₃ at 600 MHz.	13
19	Figure S19. HMBC spectrum of compound 2 recorded in CDCl ₃ at 600 MHz.	14
20	Figure S20. ¹ H- ¹ H COSY spectrum of compound 2 recorded in CDCl ₃ at 600 MHz.	14
21	Figure S21. UV spectrum of compound 2 .	15
22	Figure S22. HR-ESI-MS spectrum of compound 2 .	16
23	Figure S23. IR spectrum of compound 2 .	17
24	Figure S24. ¹ H NMR spectrum of compound 3a recorded in CDCl ₃ at 400 MHz.	17
25	Figure S25. ¹³ C NMR spectrum of compound 3a recorded in CDCl ₃ at 100 MHz.	18
26	Figure S26. ¹ H NMR spectrum of compound 3 recorded in CDCl ₃ at 600 MHz.	18
27	Figure S27. ¹³ C NMR spectrum of compound 3 recorded in CDCl ₃ at 150 MHz.	19
28	¹ H NMR and ¹³ C NMR spectral data of compounds 4-8 .	19–20







Figure S1. The first round screening of cytotoxic sites of crude extract from Dryopteris fragrans. A) against HOS cell line, B) against MG63 cell line. The asterisk indicated that there were significant differences (p < 0.05) between other crude extract and the total part. Each value represented the means ±SD of six independent experiments.







MB231-MTT








Figure S2. The second round screening of cytotoxic sites of fractions from *Dryopteris fragrans*. A) against HepG2 cell line in MTT assay at the concentration of 20 μ g/mL; B) against HepG2 cell line in MTT assay at the concentration of 40 μ g/mL; C) against HepG2 cell line in CCK-8 assay at the concentration of 40 μ g/mL; D) against MB231 cell line in MTT assay at the concentration of 20 μ g/mL; E) against MB231 cell line in MTT assay at the concentration of 40 μ g/mL; F) against MB231 cell line in CCK-8 assay at the concentration of 40 μ g/mL; G) against MG63 cell line in MTT assay at the concentration of 40 μ g/mL; H) against MG63 cell line in MTT assay at the concentration of 20 μ g/mL; G) against MG63 cell line in MTT assay at the concentration of 20 μ g/mL; H) against MG63 cell line in CCK-8 assay at the concentration of 20 μ g/mL; H) against MG63 cell line in CCK-8 assay at the concentration of 20 μ g/mL; H) against MG63 cell line in CCK-8 assay at the concentration of 20 μ g/mL; H) against MG63 cell line in CCK-8 assay at the concentration of 20 μ g/mL; H) against MG63 cell line in CCK-8 assay at the concentration of 20 μ g/mL; H) against MG63 cell line in CCK-8 assay at the concentration of 20 μ g/mL; H) against MG63 cell line in CCK-8 assay at the concentration of 20 μ g/mL. The asterisk indicates that there were significant differences (p < 0.05) between other fracions and the control group. Each value represented the means ±SD of six independent experiments.




Figure S3. ¹H-NMR spectrum of compound **1** recorded in CDCl₃ at 600 MHz.




Figure S4. ¹³C-NMR spectrum of compound **1** recorded in CDCl₃ at 150 MHz.




Figure S5. HSQC spectrum of compound 1 recorded in CDCl $_3$ at 600 MHz.




Figure S6. HMBC spectrum of compound 1 recorded in CDCl3 at 600 MHz.






Figure S7. UV spectrum of compound 1.

Page 1 of 1

Data File: E:\DATA\2017\0822\HDL-3.lcd










Figure S8. HR-ESI-MS spectrum of compound 1




Figure S9. CD spectrum of compound **1**.




Figure S10. IR spectrum of compound **1**.




Figure S11. ¹H-NMR spectrum of the mixture (2 and 3) recorded in CDCl₃ at 400 MHz




Figure S12. ¹³C-NMR spectrum of the mixture (2 and 3) recorded in CDCl₃ at 100 MHz




Figure S13. ESI-MS spectrum of the mixture (2 and 3).




Figure S14. 1H-NMR spectrum of compound 2a recorded in CDCl3 at 400 MHz.




Figure S15. ¹³C-NMR spectrum of compound 2a recorded in CDCl₃ at 100 MHz.




Figure S16. ¹H-NMR spectrum of compound **2** recorded in CDCl₃ at 600 MHz.




Figure S17. ¹³C-NMR spectrum of compound 2 recorded in CDCl₃ at 150 MHz.




Figure S18. HSQC spectrum of compound 2 recorded in CDCl₃ at 600 MHz.




Figure S19. HMBC spectrum of compound **2** recorded in CDCl₃ at 600 MHz.(Note: $\delta_{\rm H}$ 1.25 (3H, s), $\delta_{\rm C}$ 29.8 is the impurity signal of "grease")




Figure S20. 1H-1H COSY spectrum of compound 2 recorded in CDCl3 at 600 MHz.






Figure S21. UV spectrum of compound 2.

Data File: E:\DATA\2017\0926\HDL-29.lcd








Figure S23. IR spectrum of compound **2**.




Figure S24. ¹H NMR spectrum of compound 3a recorded in CDCl₃ at 400 MHz.




Figure S25. ¹³C NMR spectrum of compound **3a** recorded in CDCl₃ at 100 MHz.




Figure S26. ¹H NMR spectrum of compound **3** recorded in CDCl₃ at 600 MHz.




Figure S27. ¹³C NMR spectrum of compound 3 recorded in CDCl₃ at 150 MHz.

¹H NMR and ¹³C NMR spectral data of compounds 4-8:

vitamin E quinone (4): ¹H NMR (400 MHz, CDCl₃): δ_H 2.54 (2H, m, H-4), 2.03 (3H, s, Me-5a), 2.00 (6H, s, Me-7a, 8a), 1.49 (4H, m, H-3, 1'), 1.23 (3H, s, Me-2a), 1.45~1.00 (19H, m, methines and methylenes), 0.86 (9H, d, *J* = 7.0 Hz, H-4'a, 8'a, 12'a), 0.83 (3H, d, *J* = 7.0 Hz, H-13'); ¹³C NMR (100 MHz, CDCl₃): δ_C 187.8 (C, C-6 or C-9), 187.4 (C, C-6 or C-9), 144.6 (C, C-10), 140.7 (C, C-5), 140.6 (C, C-8), 140.3 (C, C-7), 72.7 (C, C-2), 42.4 (CH₂, C-1'), 40.4 (CH₂, C-3), 39.5 (CH₂, C-11'), 37.8 (CH₂, C-3'), 37.6 ×2 (CH₂, C-7', 5'), 37.4 (CH₂, C-9'), 32.94 (CH, C-8'), 32.91(CH, C-4'), 28.1 (CH, C-12'), 26.7 (CH₃, Me-2a), 24.9 (CH₂, C-10'), 24.6 (CH₂, C-6'), 22.9 (CH₃, Me-12'a), 22.4 (CH₃, Me-13'), 21.6 (CH₂, C-2'), 21.5 (CH₂, C-4), 19.89 (CH₃, Me-4'a), 19.85 (CH₃, Me-8'a), 12.5 (CH₃, Me-8a), 12.4 (CH₃, Me-7a), 12.1 (CH₃, Me-5a).

albicanol (**5**) : ¹H NMR (400 MHz, CDCl₃): δ_H 4.94 (1H, br s, H-12a), 4.64 (1H, br s, H-12b), 3.79 (2H, m, H-11), 2.42 (1H, ddd, *J* = 12.9, 4.4, 2.4 Hz, H-7a), 2.04 (1H, m, H-7b), 1.97 (1H, m, H-9), 1.34 (1H, dd, *J* = 12.9, 4.3 Hz, H-5), 1.76 ~ 1.00 (8H, m, H-1, 2, 3, 6), 0.87 (3H, s, Me-15), 0.80 (3H, s, Me-14), 0.72 (3H, s, Me-13); ¹³C NMR (100 MHz, CDCl₃): δ_C 148.0 (C, C-8), 106.4 (CH₂, C-12), 59.3 (CH, C-9), 58.9 (CH₂, C-11), 55.3 (CH, C-5), 42.1 (CH₂, C-3), 39.2 (CH₂, C-7), 39.2 (C, C-10), 38.0 (CH₂, C-1), 33.8 (CH₃, Me-14), 33.6 (C, C-4), 24.4 (CH₂, C-6), 21.9 (CH₃, Me-15), 19.4 (CH₂, C-2), 15.4 (CH₃, Me-13).

2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone (6): 1H NMR (400 MHz, CDCl₃): δH 13.59

(1H, s, OH-6), 5.48 (1H, br s, OH-4), 3.72 (3H, s, OMe-2), 2.69 (3H, s, 1-CO<u>CH</u>₃), 2.13 (3H, s, 3-Me or 5-Me), 2.09 (3H, s, 3-Me or 5-Me); ¹³C NMR (100 MHz, CDCl₃): δ_C 203.84 (C, 1-<u>CO</u>CH₃), 161.70 (C, C-4 or C-6), 159.39 (C, C-4 or C-6), 143.02 (C, C-2), 109.08 (C, C-3), 108.64 (C, C-5), 106.55 (C, C-1), 61.86 (CH₃, OMe-2), 31.39 (CH₃, 1-CO<u>CH₃</u>), 8.76 (CH₃, 3-Me or 5-Me), 7.61 (CH₃, 3-Me or 5-Me); negative ESI-MS: *m/z* 209 [M-H]⁻, *m/z* 419 [2M-H]⁻.

norflavesone (7): ¹H NMR (400 MHz, CDCl₃): $\delta_{\rm H}$ 3.94 (1H, m, H-8), 1.88 (3H, s, Me-13), 1.38 (6H, s, Me-11, 12), 1.12 (6H, d, *J* = 6.6 Hz, Me-9, 10); ¹³C NMR (100 MHz, CDCl₃): $\delta_{\rm C}$ 208.3 (C, C-7), 197.1 (C, C-1), 190.0 (C, C-5), 173.3 (C, C-3), 104.8 (C, C-6), 103.1 (C, C-4), 35.7 (CH, C-8), 24.7 × 2 (CH₃, C-11, 12), 19.1 × 2 (CH₃, C-9, 10), 7.0 (CH₃, C-13); ESI-MS: *m*/*z* 237[M – H]⁻.

aspidinol (8): ¹H NMR (600 MHz, CDCl₃): δ_H5.95 (1H, s, H-5), 3.82 (3H, s, MeO-4), 3.06 (2H, t, *J* = 7.4 Hz, H-2'), 2.01 (3H, s, Me-3), 1.72 (2H, m, H-3'), 0.99 (3H, *J* = 7.4 Hz, H-4'); ; ¹³C NMR (150 MHz, CDCl₃): δ_C 206.3 (C-1'), 163.2 (C-2), 160.9 (C-4), 159.8 (C-6), 104.8 (C-3), 103.2 (C-1), 91.6 (C-5), 55.8 (MeO-4), 46.3 (C-2'), 18.3 (C-3'), 14.2 (Me-4'), 7.3 (Me-3). ESI-MS: *m*/*z* 223 [M - H]⁻.